Kadimastem Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KDST.TA research report →
Price Chart
About the company
Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions.
- CEO
- Ronen Twito CPA
- IPO
- 2013
- Employees
- 11
- HQ
- Ness Ziona, IL
Get TickerSpark's AI analysis on KDST.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $125.73M
- P/E
- -3.00
- PEG
- 0.03
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -27715.80
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.08%
- ROIC
- 10.69%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,529,000+33.2%
- Op Income
- $-6,605,000
- Net Income
- $-26,552,000-120.4%
- EPS
- $-6.33-2160.7%
- OCF Growth
- +75.2%
- FCF Growth
- +75.0%
- 52W High
- $5322.95
- 52W Low
- $1558.07
- 50D MA
- $4288.64
- 200D MA
- $3526.42
- Beta
- 0.57
- RSI (14)
- 69
- Avg Volume
- 10.49K
No earnings-call transcripts are available for KDST.TA yet.
- Free Float
- 20.2%
- Shares Outstanding
- 4.50M
- Float Shares
- 909.11K
Our KDST.TA coverage
Recent articles, reports, and earnings notes.
No research on KDST.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KDST.TA report →